Perfil clínico y evolución de pacientes con hemorragia subaracnoidea durante 11 años

Clinical research[Abstract] Introduction: Spontaneous subarachnoid haemorrhage is a rare cause of stroke, but it causes great socioeconomic impact and high morbidity and mortality. The aim of this study is to describe the clinical profile and evolution of a series of patients with SAH admitted to a tertiary hospital, as well as the diagnostic and therapeutic management. Material and methods: Retrospective study of 536 patients diagnosed with SAH admitted to the ICU of the Hospital Universitario de A Coruña between 2003 and 2013 (Age: 56.9±14.1 years, female/male ratio: 1.5:1). Demographic characteristics, risk factors, aetiologies and clinical signs, prognostic scales, diagnostic tests and treatment were collected. A comparative analysis was made between the general series and subgroups of patients with aneurysmal (SAH-A) and idiopathic (SAH-I) subarachnoid haemorrhage. Results: There were 49.0±15.1 patients/year (2013 incidence: 4.3/100,000 inhabitants). 60.3% presented Glasgow Coma Scale 14-15, with scarce symptomatology (Hunt-Hess I-II 61.9%, World Federation Neurosurgeons Scale I-II 60.4%). 50.7% presented Fisher IV. SAH-A was diagnosed in 78.3% (n=396); perimesencephalic subarachnoid haemorrhage (SAH-PM) in 3.2%; and SAH-I in 17.9%. During the study period there was an increase in the prevalence of aneurysms, causing an increased number of surgeries in recent years. Both SAH-A and SAH-I presented greater severity upon admission. Patients with SAH-A had higher percentage of complications and mortality, with lesser degree of independence at 6 and 12 months. Conclusions: The incidence of SAH appears to have decreased in recent years, with SAH-I comprising 17.9% of the cases. Patients with SAH-I have better prognosis and lower risk of complications, highlighting the benignity of SAH-PM.[Resumen] Introducción. La hemorragia subaracnoidea espontánea es una causa poco frecuente de ictus que ocasiona gran impacto socioeconómico y elevada morbimortalidad. El objetivo de este estudio es describir el perfil clínico y evolución de una serie de pacientes con HSA ingresados en un hospital terciario, así como el manejo diagnóstico-terapéutico. Material y métodos. Estudio retrospectivo de 536 pacientes diagnosticados de HSA ingresados en la Unidad de Cuidados Intensivos del Hospital Universitario de A Coruña de 2003–2013 (edad: 56,9 ± 14,1 años, ratio mujer/hombre:1,5:1). Se recogieron características demográficas, factores de riesgo, etiología y clínica, escalas pronósticas, pruebas diagnósticas y tratamiento. Se realizó un análisis comparativo entre la serie general y subgrupos de pacientes con HSA aneurismática (HSA-A) e idiopática (HSA-I). Resultados. Se registraron 49,0 ± 15,1 pacientes/año (incidencia 2013:4,3/100.000 habitantes). 60,3% presentaban Glasgow Coma Scale 14-15, con escasa sintomatología (Hunt-Hess (H-H) I-II 61,9%; World Federation Neurosurgeons Scale (WFNS) I-II 60,4%). 50,7% presentaban Fisher IV. En 78,3%(n = 396) se diagnosticó HSA-A, 3,2% presentaban sangrado perimesencefálico (HSA-PM) y HSA-I 17,9%. Durante el periodo de estudio se registró aumento de la prevalencia de aneurismas, incrementándose en los últimos años la cirugía. Tanto la HSA-A como HSA-I presentaban mayor gravedad al ingreso. Los pacientes con HSA-A presentaron mayor porcentaje de complicaciones y mortalidad, con menor grado de independencia a 6 y 12 meses. Conclusiones. La incidencia de HSA tiende a descender en los últimos años, representando la HSA-I el 17,9% de los casos. Los pacientes con HSA-I tienen mejor pronóstico y menor riesgo de complicaciones, destacando la benignidad de la HSA-PM

Epidemiological study of tricuspid regurgitation after cardiac transplantation: does it influence survival?

Observational study[Abstract] Background: Tricuspid valve disease is the most frequent valvulopathy after heart transplantation (HTx). Evidence for the negative effect of post-transplant tricuspid regurgitation (TR) on survival is contradictory. The aim of this study was to analyze the causes of post-transplant TR and its effect on overall mortality. Methods: This is a retrospective observational study of all transplants performed in two Spanish centers (1009 patients) between 2000 and 2019. Of the total number of patients, 809 had no TR or mild TR and 200 had moderate or severe TR. The etiology of TR was analyzed in all cases. Results: The prevalence of moderate and severe TR was 19.8%. The risk of mortality was greater when TR was caused by early primary graft failure (PGF) or rejection (p < 0.05). TR incidence was related to etiology: incidence of PGF-induced TR was higher in the first period, while TR due to rejection and undefined causes occurred more frequently in three periods: in the first year, in the 10-14-year period following HTx, and in the long term (16-18 years). In the multivariable analysis, TR was significantly associated with mortality/retransplantation (HR:1.04, 95% CI:1.01-1.07, p:0.02). Conclusion: The development of TR after HTx is relatively frequent. The annual incidence depends on TR severity and etiology. The risk of mortality is greater in severe TR due to PGF or rejection

Incidencia, factores de riesgo e impacto pronóstico de la infección por citomegalovirus tras el trasplante cardiaco

[Abstract] Introduction and objectives. To assess the risk factors of CMV infection after heart transplant (HT) and its influence on long-term prognosis. Methods. We conducted a retrospective single-centre study of 222 H T recipients. Risk factors for CMV infection were identified by means of multivariable Cox´s regression. Kaplan-Meier analysis and Cox´s regression were used to assess the long-term prognostic impact of CMV infection during the first post-transplant year. Results. Donor-recipient CMV serologic matching (hazard ratio [HR] 1.92, 95% confidence interval [95% CI] 1.2–3.09, p = .007), recipient age (HR 1.02, 95% CI 1.00–1.1, p = .02), diabetes mellitus (HR 1.86, 95% CI 1.4–3.05, p = .01), pre- transplant circulatory support (HR 1.59, 95% CI 1.06–2.38, p = .03) and the use of tacrolimus (HR 1.64, 95% CI 1.13–2.36, p = .009) were independently associated with increased risk of CMV infection. CMV infection during the first year post-HT was not associated with worse transplant outcomes in terms of mortality, incidence of heart failure, cardiac allograft vasculopathy or acute rejection. Conclusions. CMV infection was not associated with impaired long-term prognosis after HT.[Resumen] Introducción y objetivos. Analizar el impacto pronóstico de la infección por Citomegalovirus (CMV) durante el primer año tras el trasplante cardiaco (TC) y describir factores de riesgo. Métodos. Se realizó un estudio retrospectivo unicéntrico incluyendo 222 receptores de TC. La identificación de factores de riesgo de infección por CMV se llevó a cabo mediante regresión multivariable de Cox. Mediante los métodos de Kaplan-Meier y Cox se analizó la influencia de la infección por CMV durante el primer año sobre la supervivencia e incidencia de eventos clínicos adversos en el seguimiento a largo plazo. Resultados. En el análisis multivariante, el estado serológico donante/receptor frente a CMV (hazard ratio [HR] 1,92, intervalo de confianza 95% [IC 95%] 1,2–3,09; p = 0007, la edad del receptor HR 1,02, IC 95% 1,00–1,1; p = 0,02), la diabetes (HR 1,86, IC 95% 1,4-3,05; p = 0,01), el soporte circulatorio mecánico (HR 1,59, IC 95% 1,06-2,38; p = 0,03) y el uso de tacrolimus (HR 1,64, IC 95% 1,13-2,36; p = 0009, resultaron predictores independientes de infección por CMV post-trasplante. No se detectó una influencia significativa de la infección por CMV durante el primer año post-trasplante sobre la mortalidad, la incidencia de insuficiencia cardiaca, enfermedad vascular del injerto o rechazo agudo. Conclusiones. La infección por CMV durante el primer año post-trasplante no se asoció a un peor pronóstico a largo plazo

Prevalence of tricuspid regurgitation after orthotopic heart transplantation and its evolution in the follow-up period: a long-term study

[Abstract] Background. Tricuspid regurgitation (TR) after heart transplant (HT) can be an important complication depending on its etiology and severity. This study aims to analyze the prevalence of TR, the causes, and its evolution over time after HT. Methods. We performed a retrospective study of transplants performed between 2000 and 2019 in 2 centers (1009 patients). TR was grouped according to etiology: primary graft dysfunction (PGD), acute rejection, cardiac allograft vasculopathy (CAV), pulmonary hypertension, prolapse, endomyocardial biopsy complication (EMB), pacemaker (PM), and unclear etiology (TR not related to any process and for which no justification was found). Results. The prevalence of TR after HT was 19.8% (moderate: 13.2%, severe: 6.6%). Significant TR was more prevalent in the first months (month 1: 51%, month 3: 40%, month 6: 29%, 1 year: 24%). These results were related to the etiologies. Thus, in the first month, TR due to PGD is frequent and it is the only time when TR due to pulmonary hypertension appears. During the first 6 months, TR of unclear cause gains relevance, which tends to decrease over time. After 1 year, TR due to rejection predominates. After 5 years, TR is less frequent (< 10%) and related to long-term complications of HT, such as CAV, EMB, and those associated with PM. Conclusions. The prevalence of TR after HT is 19.8%. Prevalence and etiology change over time. Initially it is usually related to PGD, in the medium-term to rejection and in the long-term to CAV and procedures such as EMB and PM

Survival effect after a therapeutic hypothermia protocol implementation

OBJETIVE. To evaluate whether implementation of a therapeutic hypothermia (TH) protocol improved survival and neurologic outcomes in patients successfully resuscitated from cardiac arrest. METHOD AND PATIENTS. A Retrospective Historic Cohort Study realized in a Cardiac Intensive Care Unit from January 2007 to December 2010. An active cooling therapeutic hypothermia protocol, using a cooling surface method with hydrogel patches (Arctic Sun) to achieve a temperature of 33degreeC for 24 h was initiated on July 2009 for unconscious patients resuscitated from cardiac arrest. The device is connected to a temperature control console, measuring core temperature with an urinary catheter. In this study we compare patients who presented after implementation of a therapeutic hypothermia protocol with those who presented before the protocol was implemented. Demographics and outcomes were obtained from an intensive care medical database. RESULTS. A total of 81 consecutive adults, with nontraumatic cardiac arrest, admitted between January 2007 and December 2010 were included, 35 on TH group and 46 on control group. Both groups were similar with no statistic differences on personal previous medical history characteristics or cardiopulmonary resuscitation time. The only differences between groups was a greater number of patients with ventricular fibrillation (VF) as an initial rhythm and ECG changes in the TH group (72, 7%, p = 0.059), which results in a greater coronarography number (65.7%, p<0.001). Mortality at hospital discharge decreased in the therapeutic hypothermia group (p = 0.005, OR 0.154, 95% IC 0.043-0.546). In adjusted analysis, VF as an initial rhythm (p<0.05, OR 0.30, 95% confidence interval 0.096-0.96), short resuscitation time period (p = 0.02, OR 1.085, CI 1.013-1.162) and younger patients (p = 0.018, OR 1.055, CI 1.010-1.102) also result in a better survival. CONCLUSIONS. The implementation of a therapeutic hypothermia (TH) protocol was associated with a signifi